KEY FEATURES
| Full Name | Apolipoprotein A2 |
|---|---|
| Synonym | Apo-A2; Apolipoprotein A-II; ProapoA-II; Truncated apolipoprotein A-II |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.78-50ng/mL |
| Sensitivity | 0.27ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human APOA2 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human APOA2. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human APOA2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human APOA2, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human APOA2. You can calculate the concentration of Human APOA2 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human APOA2 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 2.33 | 6.6 | 17.02 | 2.52 | 6.41 | 18.72 |
| Standard deviation | 0.12 | 0.36 | 0.64 | 0.14 | 0.29 | 0.92 |
| CV(%) | 5.03 | 5.43 | 3.75 | 5.64 | 4.59 | 4.9 |
RECOVERY
The recovery of Human APOA2 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 92-107 | 98 |
| EDTA plasma (n=8) | 89-100 | 94 |
| Cell culture media (n=8) | 89-104 | 95 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human APOA2 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with LPA ELISA Kits
| APOA1 ELISA Kit | publications with LPA and APOA1 |
| APOE ELISA Kit | publications with LPA and APOE |
| APOB ELISA Kit | publications with LPA and APOB |
| APOC2 ELISA Kit | publications with LPA and APOC2 |
| APOC3 ELISA Kit | publications with LPA and APOC3 |
| APOA4 ELISA Kit | publications with LPA and APOA4 |
| LPL ELISA Kit | publications with LPA and LPL |
| APOA5 ELISA Kit | publications with LPA and APOA5 |
| APOH ELISA Kit | publications with LPA and APOH |
Pathways associated with LPA ELISA Kit
| Chylomicron-mediated Lipid Transport Pathway | Chylomicron-mediated Lipid Transport Pathway |
| Complement And Coagulation Cascades Pathway | Complement And Coagulation Cascades Pathway |
| Disease Pathway | Disease Pathway |
| Diseases Associated With Visual Transduction Pathway | Diseases Associated With Visual Transduction Pathway |
| Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway | Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway |
| Lipid Digestion, Mobilization, And Transport Pathway | Lipid Digestion, Mobilization, And Transport Pathway |
| Lipoprotein Metabolism Pathway | Lipoprotein Metabolism Pathway |
| Metabolism Pathway | Metabolism Pathway |
| Metabolism Of Lipids And Lipoproteins Pathway | Metabolism Of Lipids And Lipoproteins Pathway |
| PPAR Signaling Pathway | PPAR Signaling Pathway |
Diseases associated with LPA ELISA Kit
| Cardiovascular Diseases | publications with LPA and Cardiovascular Diseases |
| Dyslipidemias | publications with LPA and Dyslipidemias |
| Liver Diseases | publications with LPA and Liver Diseases |
| Hyperlipidemias | publications with LPA and Hyperlipidemias |
| Heart Diseases | publications with LPA and Heart Diseases |
| Inflammation | publications with LPA and Inflammation |
| Disease Models, Animal | publications with LPA and Disease Models, Animal |
| Kidney Diseases | publications with LPA and Kidney Diseases |
| Hepatitis | publications with LPA and Hepatitis |
| Carcinoma, Hepatocellular | publications with LPA and Carcinoma, Hepatocellular |
Organs/Tissues associated with LPA ELISA Kit
| Blood | publications with LPA and Blood |
| Liver | publications with LPA and Liver |
| Heart | publications with LPA and Heart |
| Kidney | publications with LPA and Kidney |
| Muscle | publications with LPA and Muscle |
| Intestine | publications with LPA and Intestine |
| Brain | publications with LPA and Brain |
| Placenta | publications with LPA and Placenta |
| Lung | publications with LPA and Lung |
| Spleen | publications with LPA and Spleen |